title: Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
abstract: BACKGROUND
  Although 5-fluorouracil (5-FU)-related cardiotoxicity is well known, atrial arrhythmia, as a potentially serious complication has not been studied in detail. The aim of this study was to determine the P max and Pd in the electrocardiograms (ECG) of patients receiving 5-FU treatment.
  
  
  METHODS
  Twenty-five patients (mean age: 62 years) receiving a 5-FU bolus plus continuous infusion with calcium leucovorin over 48 h and with normal pre-treatment cardiac physical examinations, ECG and echocardiography were enrolled. P maximum (P max), P minimum (P min) and P dispersion (Pd) (maximum minus minimum P wave duration) were measured from the 12-lead ECG at the 0th and 48th hour of the first chemotherapy cycle. Echocardiography was also obtained in all patients at the same times.
  
  
  RESULTS
  Clinical cardiotoxicity was observed in two patients. P max and Pd were both significantly longer after 5-FU treatment at the 48th hour (P < 0.001). P min did not change (P > 0.05).
  
  
  CONCLUSIONS
  Treatment with 5-FU based regimens may increase Pd and prolong the P max in cancer patients. These alterations may be predictive of patients at risk of atrial arrhythmias during 5-FU treatment.
authors.affiliation: Department of Cardiology, School of Medicine, Adnan Menderes University, Aydin 09100, Turkey. ceyhunceyhan@yahoo.com
authors.forename: C
authors.initials: C
authors.lastname: Ceyhan
authors.forename: N
authors.initials: N
authors.lastname: Meydan
authors.forename: S
authors.initials: S
authors.lastname: Barutca
authors.forename: T
authors.initials: T
authors.lastname: Tekten
authors.forename: A O
authors.initials: AO
authors.lastname: Onbasili
authors.forename: B
authors.initials: B
authors.lastname: Ozturk
authors.forename: S
authors.initials: S
authors.lastname: Unal
authors.forename: I
authors.initials: I
authors.lastname: Bayrak
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D002277:Carcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D003329:Coronary Vasospasm / Q000139:chemically induced; D003331:Coronary Vessels / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004452:Echocardiography / Q000379:methods; D004562:Electrocardiography / Q000187:drug effects* / Q000379:methods; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D013274:Stomach Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors
chemical_list: D002955:Leucovorin; D005472:Fluorouracil